## **Core Concept**
The question tests knowledge of pharmacological management of central diabetes insipidus, focusing on selective V2 receptor agonists. Central diabetes insipidus is a condition characterized by the inability to regulate fluids in the body due to insufficient production of antidiuretic hormone (ADH), also known as vasopressin. V2 receptors are primarily found in the kidneys and play a crucial role in water reabsorption.

## **Why the Correct Answer is Right**
Desmopressin is a synthetic analogue of vasopressin that selectively acts on V2 receptors. By activating V2 receptors in the kidneys, desmopressin increases water permeability in the collecting ducts, leading to water reabsorption and reduced urine output. This mechanism makes desmopressin highly effective in treating central diabetes insipidus.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While this could potentially be a drug, without specifying, it's hard to assess its relevance, but generally, it's not recognized as a first-line treatment for central diabetes insipidus.
- **Option B:** This option does not directly correspond with known treatments for central diabetes insipidus and lacks specificity.
- **Option D:** Vasopressin itself is not selective for V2 receptors; it has broad effects including vasoconstriction through V1 receptors, making it less ideal for this specific condition.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that desmopressin has a more targeted action than vasopressin, reducing side effects like vasoconstriction. It's often administered intranasally or orally, making it convenient for patients with central diabetes insipidus.

## **Correct Answer:** . Desmopressin